Performance of a limiting-antigen avidity enzyme immunoassay for cross-sectional estimation of HIV incidence in the United States

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Konikoff, Jacob ^a   Brookmeyer, Ron ^a   Longosz, Andrew F ^b   Cousins, Matthew M ^c   Celum, Connie ^d   Buchbinder, Susan P ^e   Seage III, George R ^f   Kirk, Gregory D ^g   Moore, Richard D ^c   Mehta, Shruti H ^c   Margolick, Joseph B ^g   Brown, Joelle ^a   Mayer, Kenneth H ^f   Koblin, Beryl A ^h   Justman, Jessica E ⁱ   Hodder, Sally L ^j   Quinn, Thomas C ^b   Eshleman, Susan H ^c   Laeyendecker, Oliver ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e HIV STD and Hepatitis Branch   (United States)

^f HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^g JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^h NEW YORK BLOOD CENTER   (United States)

ⁱ Columbia University Mailman School of Public Health ^*  (United States)

^j RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALGORITHMS; ANTIBODY AFFINITY; BIOLOGICAL MARKERS; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDIES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOENZYME TECHNIQUES; INCIDENCE; UNITED STATES; VIRAL LOAD;

EID: 84893554240     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0082772     Document Type: Article

References (43)

1. Brookmeyer R (2010) Measuring the HIV/AIDS epidemic: approaches and challenges. Epidemiol Rev 32: 26-37.
2. Mastro TD, Kim AA, Hallett T, Rehle T, Welte A, et al. (2010) Estimating HIV Incidence in Populations Using Tests for Recent Infection: Issues, Challenges and the Way Forward. J HIV AIDS Surveill Epidemiol 2: 1-14.
3. Busch MP, Pilcher CD, Mastro TD, Kaldor J, Vercauteren G, et al. (2010) Beyond detuning: 10 years of progress and new challenges in the development and application of assays for HIV incidence estimation. AIDS 24: 2763-2771.
4. Brookmeyer R, Quinn T, Shepherd M, Mehendale S, Rodrigues J, et al. (1995) The AIDS epidemic in India: a new method for estimating current human immunodeficiency virus (HIV) incidence rates. Am J Epidemiol 142: 709-713. (Pubitemid 26434970)
5. Laeyendecker O, Brookmeyer R, Mullis CE, Donnell D, Lingappa J, et al. (2012) Specificity of four laboratory approaches for cross-sectional HIV incidence determination: analysis of samples from adults with known nonrecent HIV infection from five African countries. AIDS Res Hum Retroviruses 28: 1177-1183.
6. Laeyendecker O, Brookmeyer R, Oliver AE, Mullis CE, Eaton KP, et al. (2012) Factors associated with incorrect identification of recent HIV infection using the BED capture immunoassay. AIDS Res Hum Retroviruses 28: 816-822.
7. Mullis CE, Munshaw S, Grabowski MK, Eshleman SH, Serwadda D, et al. (2013) Differential specificity of HIV incidence assays in HIV subtypes A and D-infected individuals from Rakai, Uganda. AIDS Res Hum Retroviruses.Epub available online.
8. Marinda ET, Hargrove J, Preiser W, Slabbert H, van Zyl G, et al. (2010) Significantly diminished long-term specificity of the BED capture enzyme immunoassay among patients with HIV-1 with very low CD4 counts and those on antiretroviral therapy. J Acquir Immune Defic Syndr 53: 496-499.
9. Hayashida T, Gatanaga H, Tanuma J, Oka S (2008) Effects of low HIV type 1 load and antiretroviral treatment on IgG-capture BED-enzyme immunoassay. AIDS Res Hum Retroviruses 24: 495-498. (Pubitemid 351457743)
10. Murphy G, Parry JV (2008) Assays for the detection of recent infections with human immunodeficiency virus type 1. Euro Surveill 13: pii18966.
11. Guy R, Gold J, Calleja JM, Kim AA, Parekh B, et al. (2009) Accuracy of serological assays for detection of recent infection with HIV and estimation of population incidence: a systematic review. Lancet Infect Dis 9: 747-759.
12. Dobbs T, Kennedy S, Pau CP, McDougal JS, Parekh BS (2004) Performance characteristics of the immunoglobulin G-capture BED-enzyme immunoassay, an assay to detect recent human immunodeficiency virus type 1 seroconversion. J Clin Microbiol 42: 2623-2628. (Pubitemid 38747513)
13. Masciotra S, Dobbs T, Candal D, Hanson D, Delaney K, et al. (2010) Antibody avidity-based assay for identifying recent HIV-1 infection based on a genetic systems 1/2 + O EIA. 17th Conference on Retroviruses and Opportunistic Infections. February 16-19. San Francisco, CA: Abstract 937.
14. Brookmeyer R, Konikoff J, Laeyendecker O, Eshleman SH (2013) Estimation of HIV incidence using multiple biomarkers. Am J Epidemiol 177: 264-272.
15. Cousins MM, Laeyendecker O, Beauchamp G, Donnell D, Coates T, et al. (2012) Multi-region analysis may enhance the utility of HIV diversity as a biomarker for HIV incidence determination. 19th Conference on retroviruses and Opportunistic Infections. March 5-8. Seattle, WA: Abstract 539.
16. Brookmeyer R, Laeyendecker O, Donnell D, Eshleman SE (2013) Cross-Sectional HIV incidence estimation in HIV prevention research. J Acquir Immune Defic Syndr 63: S233-S239.
17. Wei X, Liu X, Dobbs T, Kuehl D, Nkengasong JN, et al. (2010) Development of two avidity-based assays to detect recent HIV type 1 seroconversion using a multisubtype gp41 recombinant protein. AIDS Res Hum Retroviruses 26: 61-71.
18. Duong YT, Qiu M, De AK, Jackson K, Dobbs T, et al. (2012) Detection of recent HIV-1 infection using a new limiting-antigen avidity assay: potential for HIV-1 incidence estimates and avidity maturation studies. PLoS One 7: e33328.
19. Centers for Disease Control and Prevention (2010) Prevalence and awareness of HIV infection among men who have sex with men - 21 cities, United States, 2008. MMWR Morb Mortal Wkly Rep 59: 1201-1207.
20. Freiden T (2013) Remarks from the Director of the US Centers for Disease Control and Prevention. 20th Conference on Retroviruses and Oppurtunistic Infections. Atlanta, GA: CROI, LLC.
21. Kassanjee R, Murphy G, Busch M, Pilcher CD, McKinney E, et al. (2013) The performance of candidate assays to detect HIV infection for cross-sectional incidence estimation: an independent, comparative evaluation. 20th Conference on Retroviruses and Opportunistic Infections March 3-6. Atlanta, GA: Abstract 1056.
22. Mastro TD (2013) Determining HIV incidence in populations: Moving in the right direction. J Infect Dis 207: 204-206.
23. Sedia Biosciences Corporation (2013) Sedia HIV-1 LAg-Avidity EIA. LN 6039, 04 ed. Portland, OR.
24. Sedia Biosciences Corporation (2013) Sedia HIV-1 LAg-Avidity EIA. LN 6039, 05 ed. Portland, OR.
25. Kaslow RA, Ostrow DG, Detels R, Phair JP, Polk BF, et al. (1987) The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants. Am J Epidemiol 126: 310-318. (Pubitemid 17102758)
26. Vlahov D, Anthony JC, Munoz A, Margolick J, Nelson KE, et al. (1991) The ALIVE study, a longitudinal study of HIV-1 infection in intravenous drug users: description of methods and characteristics of participants. NIDA Res Monogr 109: 75-100. (Pubitemid 23095616)
27. Celum CL, Buchbinder SP, Donnell D, Douglas JM, Jr., Mayer K, et al. (2001) Early human immunodeficiency virus (HIV) infection in the HIV Network for Prevention Trials Vaccine Preparedness Cohort: risk behaviors, symptoms, and early plasma and genital tract virus load. J Infect Dis 183: 23-35. (Pubitemid 32043038)
28. Moore RD (1998) Understanding the clinical and economic outcomes of HIV therapy: the Johns Hopkins HIV clinical practice cohort. J Acquir Immune Defic Syndr Hum Retrovirol 17 Suppl 1: S38-41.
29. Laeyendecker O, Brookmeyer R, Cousins MM, Mullis CE, Konikoff J, et al. (2013) HIV incidence determination in the United States: a multiassay approach. J Infect Dis 207: 232-239.
30. Koblin B, Mayer K, Eshleman SH, Wang L, Shoptaw S, et al. (2013) Correlates of HIV acquisition in a cohort of Black men who have sex with men in the United States: HIV Prevention Trials Network (HPTN) 061. PLoS One In Press.
31. Hodder SL, Justman J, Hughes JP, Wang J, Haley DF, et al. (2013) HIV acquisition among women from selected areas of the United States: a cohort study. Ann Intern Med 158: 10-18.
32. Fiebig EW, Wright DJ, Rawal BD, Garrett PE, Schumacher RT, et al. (2003) Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 17: 1871-1879. (Pubitemid 37070272)
33. Kaplan EH, Brookmeyer R (1999) Snapshot estimators of recent HIV incidence rates. Oper Res 47: 29-37. (Pubitemid 129700855)
34. Brookmeyer R (2010) On the statistical accuracy of biomarker assays for HIV incidence. J Acquir Immune Defic Syndr 54: 406-414.
35. Brookmeyer R (1997) Accounting for follow-up bias in estimation of human immunodeficiency virus incidence rates. J Roy Stat Soc a Sta 160: 127-140.
36. Parekh B, Duong Y, Mavengere Y, Dobbs T, Chang J, et al. (2012) Performance of new LAg-Avidity EIA to measure HIV-1 incidence in a cross-sectional population: Swaziland HIV incidence measurement survey (SHIMS). XIX International AIDS Conference. July 22-27. Washington DC: Abstract LBPE27.
37. Celum C, Buchbinder S, Donnell D, Douglas J, Mayer K, et al. (2001) Early human immunodeficiency virus (HIV) infection in the HIV network for prevention trials vaccine preparedness cohort: Risk behaviors, symptoms, and early plasma and genital tract virus load. J Infect Dis 183: 23-35. (Pubitemid 32043038)
38. Sullivan AK, Savage EJ, Lowndes CM, Paul G, Murphy G, et al. (2013) Non-disclosure of HIV status in UK sexual health clinics-a pilot study to identify non-disclosure within a national unlinked anonymous seroprevalence survey. Sex Transm Infect 89: 120-121.
39. Fogel JM, Wang L, Parsons TL, Ou S-S, Piwowar-Manning E, et al. (2013) Undisclosed antiretroviral drug use in a multi-national clinical trial (HPTN 052). J Infect Dis In press.
40. Kahle EM, Kashuba A, Baeten JM, Fife K, Celum C, et al. (2013) Unreported antiretroviral use by HIV-1 infected participants enrolling in a prospective research study. J Acquir Immune Defic Syndr In press.
41. Masciotra S, Wei X, Luo W, Smith A, Miles I, et al. (2013) Performance of dried blood spots with a modified Genetic Systems HIV 1/2 +plus O avidity based assay for idenitfying recent HIV infections. 20th Conference on Retroviruses and Opportunistic Infections. March 3-6. Atlanta, GA: Abstract 1055.
42. Young CL, Hu DJ, Byers R, Vanichseni S, Young NL, et al. (2003) Evaluation of a sensitive/less sensitive testing algorithm using the bioMerieux Vironostika-LS assay for detecting recent HIV-1 subtype B9 or E infection in Thailand. AIDS Res Hum Retroviruses 19: 481-486. (Pubitemid 36793768)
43. Parekh BS, Hanson DL, Hargrove J, Branson B, Green T, et al. (2011) Determination of mean recency period for estimation of HIV type 1 Incidence with the BED-capture EIA in persons infected with diverse subtypes. AIDS Res Hum Retroviruses 27: 265-273.